Medicenna Therapeutics Corp. · TSX:MDNA
Medicenna Therapeutics — Corporate Update (August 2022)
10 slides from Medicenna Therapeutics's corporate update, Aug 15, 2022
Slide 1: ABILITY Study of MDNA11: clinical data update and safety
On May 2, 2022, Medicenna announced new clinical data from the third cohort of the Phase 1/2 ABILITY Study of MDNA11. This data was subsequently updated in July as described below. On May 11, 2022 , Medicenna presented additional clinical data from the Phase 1/2 ABILITY Study during a poster present
Slide 2: Pharmacokinetics
Pharmacokinetics: - The pharmacokinetic data from the first 3 cohorts demonstrated similar trends following each of 3 repeat doses which suggests lack of immunogenicity or insignificant levels of anti-drug-antibodies. - Dose dependent increase in the C max and Area Under the Curve (“AUC”) were also
Slide 3: Pharmacodynamics
Pharmacodynamics: - In addition to dose dependent increases in lymphocyte counts and lymphocyte kinetics, MDNA11 preferentially expanded anti-cancer NK and CD8 + T cells without stimulating proliferation of pro-tumor Treg cells.
Slide 4: MDNA11 Induced Lymphocyte Expansion
MDNA11 Induced Lymphocyte Expansion > Expansion of circulating lymphocytes irrespective of baseline count @ <l0ugkg OD 30ugkg SOUR Peak Fold-Change 4 4 MDNAI1 . a Lumpy Count (10 pe yi) SSSI PFIISSSESES sists 2 60 uelkg ‘Peak fold-change retative to basoling. Pr Sapte oemnerak camer FeeiB ghd 3 phon
Slide 5: MDNA11 Stimulated CD8+ T and NK Cell Proliferation (Ki67)
MDNA11 Stimulated CD8+ T and NK Cell Proliferation (Ki67) > No increase in Tregs DL3: 30 pg/kg. DL4: 60 pg/kg g 3” = Ew. y § cf ge i Ev. i i CORT NK Treg Coe T NK Treg etre to respacne se (010 fr 02:P203 fr O18)
Slide 6: MDNA11 activation of anti-cancer CD8+ T cells
- MDNA11 treatment potently activated anti-cancer CD8 + T cells as shown by increases in both CD25 + and ICOS + CD8 + T cells. - Unlike IL-2, MDNA11 has not induced increases in ICOS + Treg cells. ICOS + Treg cells are highly immunosuppressive and associated with lack of response to high dose IL-2 i
Slide 7: Anti-tumor Activity
Anti-tumor Activity: - Of the ten (10) evaluable patients with at least one on-treatment imaging scan, four (4) patients have achieved tumor control (defined as stable disease, partial response, or complete response as per RECIST 1.1) during the monotherapy dose-escalation portion of the MDNA11 ABIL
Slide 8: BiSKITs Platform and upcoming milestones
BiSKITs TM (Bi-functional SuperKine ImmunoTherapies) Platform Our BiSKITs TM platform allows us to develop designer Superkines by fusing them to other proteins, antibodies, cytokines or other Superkines to combine two distinct but synergistic functions into one molecule: a BiSKIT TM . Medicenna anti
Slide 9: Murine tumor model data for MDNA223
Data from murine tumor models using a mouse version of MDNA223 (i.e MDNA223m) showed dose-dependent and statistically significant improvements in efficacy compared to co-administration of the anti-PD-1 antibody and IL-2 super-agonist (MDNA19) at equivalent molar doses, demonstrating the advantage of
Slide 10: Fc-MDNA413 preclinical data and financial summary
On April 8, 2022, Medicenna announced new preclinical data on its long-acting IL-13 super-antagonist, Fc-MDNA413, in an electronic poster at the AACR Annual Meeting. Fc-MDNA413 is derived from Medicenna’s Superkine platform and comprises of an IL-13 super-antagonist (MDNA413) fused to the Fc domain
Medicenna Therapeutics — Corporate Update (August 2022) on 6ix